焦庆昉;宋方洲;易发平;

• 1:重庆医科大学免疫学教研室
• 2:重庆医科大学分子医学与肿瘤研究中心
• 3:重庆医科大学生物化学与分子生物学教研室

摘要(Abstract)：

宫颈癌是妇科最常见的恶性肿瘤之一,其发病率在女性恶性肿瘤中居第2位。树突状细胞(DC)是机体免疫应答的始动者,以DC为基础的抗肿瘤免疫治疗已成为热点。本文就树突状细胞的抗肿瘤机制及其在宫颈癌免疫治疗中的应用作一综述。

关键词(KeyWords)： 树突状细胞;疫苗;宫颈癌;免疫治疗

Abstract:

Keywords:

基金项目(Foundation): 国家自然科学基金项目(30800945);; 重庆市科委自然科学基金项目(CSTC,2008BB5225)

作者(Authors): 焦庆昉;宋方洲;易发平;

DOI: 10.13200/j.cjb.2010.04.115.jiaoqf.019

参考文献(References)：

• [1]Galani E,Christodoulou C.Human papilloma viruses and cancer in the post-vaccine era.Clin Microbiol Infect,2009,15(11):977-981.
• [2]Bellone S,El-Sahwi K,Cocco E,et al.Human papillomavirus type16(HPV-16)virus-like particle L1-specific CD8+cytotoxic T lymphocytes(CTLs)are equally effective as E7-specific CD8+CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients:implications for L1dendritic cell-based therapeutic vaccines.J Virol,2009,83(13):6779-6789.
• [3]Wang K,Zhou Q,Guo AL,et al.An autologous therapeutic den-dritic cell vaccine transfected with total lung carcinoma RNA stim-ulates cytotoxic T lymphocyte responses against non-small cell lung cancer.Immunol Invest,2009,38(7):665-680.
• [4]Cohen S,Haimovich J,Hollander N.Dendritic cell-based therapeu-tic vaccination against myeloma:vaccine formulation determines ef-ficacy against light chain myeloma.J Immunol,2009,182(3):1667-1673.
• [5]Deng YJ,Zhang LJ,Su XD,et al.Dendritic cell-tumor cell fusion vaccine prevents growth of subcutaneous transplanted esophageal carcinomas.Chin J Cancer,2009,28(10):1067-1071.
• [6]Troy A,Davidson P,Atkinson C,et al.Phenotypic characterisation of the dendritic cell infiltrate in prostate cancer.J Urol,1998,160(1):214-219.
• [7]Gabrilovich DI,Corak J,Ciernik IF,et al.Decreased antigen pre-sentation by dendritic cells in patients with breast cancer.Clin Cancer Res,1997,3(3):483-490.
• [8]Quah BJ,O'Neill HC.The immunogenicity of dendritic cell-derived exosomes.Blood Cells Mol Dis,2005,35(2):94-110.
• [9]Gabrilovich D.Mechanisms and functional significance of tumour-induced dendritic-cell defects.Nat Rev Immunol,2004,4(12):941-952.
• [10]Takahashi A,Kono K,Ichihara F,et al.Vascular endothelial growth factor inhibits maturation of dendritic cells induced by lipopolysaccharide,but not by proinflammatory cytokines.Cancer Immunol Immunother,2004,53(6):534-550.
• [11]Kobayashi A,Weinberg V,Darragh T,et al.Evolving immuno-suppressive microenvironment during human cervical carcino-genesis.Mucosal Immunol,2008,1(5):412-420.
• [12]Menetrier-Caux C,Montmain G,Dieu MC,et al.Inhibition of the differentiation of dendritic cells from CD34+progenitors by tumor cells:role of interleukin-6and macrophage colony-stimulating factor.Blood,1998,92(12):4778-4791.
• [13]Zhang G,Sun L,Li Z,et al.HPV-16E6can induce multiple site phosphorylation of p53.Oncol Rep,2009,21(2):371-377.
• [14]Yugawa T,Kiyono T.Molecular mechanisms of cervical carcino-genesis by high-risk human papillomaviruses:novel functions of E6and E7oncoproteins.Rev Med Virol,2009,19(2):97-113.
• [15]Tseng CW,Hung CF,Alvarez RD,et al.Pretreatment with cis-platin enhances E7-specific CD8+T-Cell-mediated antitumor im-munity induced by DNA vaccination.Clin Cancer Res,2008,14(10):3185-3192.
• [16]Zheng Y,Zhang Y,Ma Y,et al.Enhancement of immunothera-peutic effects of HPV16E7on cervical cancer by fusion with CT-LA4extracellular region.J Microbiol,2008,46(6):728-736.
• [17]Daniel D,Chiu C,Giraudo E,et al.CD4+T cell-mediated anti-gen-specific immunotherapy in a mouse model of cervical cancer.Cancer Res,2005,65(5):2018-2025.
• [18]Hauser H,Shen L,Gu QL,et al.Secretory heat-shock protein as a dendritic cell-targeting molecule:a new strategy to enhance the potency of genetic vaccines.Gene Ther,2004,11(11):924-932.
• [19]Mandic A,Vujkov T.Human papillomavirus vaccine as a new way of preventing cervical cancer:a dream or the future.Ann Oncol,2004,15(2):197-200.
• [20]Ault KA,Future II Study Group.Effect of prophylactic human papillomavirus L1virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade2,grade3,and adenocarcinoma in situ:a combined analysis of four randomised clinical trials.Lancet,2007,369(9576):1861-1868.
• [21]De Witte L,Zoughlami Y,Aengeneyndt B,et al.Binding of hu-man papilloma virus L1virus-like particles to dendritic cells is mediated through heparan sulfates and induces immune activa-tion.Immunobiology,2007,212(9-10):679-691.
• [22]Remondo C,Cereda V,Mostbck S,et al.Human dendritic cell maturation and activation by a heat-killed recombinant yeast(Saccharomyces cerevisiae)vector encoding carcinoembryonic antigen.Vaccine,2009,27(7):987-994.
• [23]Zhou CJ,Ma W,Zhou JD,et al.Killing activity of cytotoxic T lymphocytes stimulated by dendritic cell vaccine loaded with au-tologous cervical cancer antigen.Ai Zheng,2006,25(2):143-147.
• [24]Chandy AG,Nurkkala M,Josefsson A,et al.Therapeutic dendrit-ic cell vaccination with Ag coupled to cholera toxin in combina-tion with intratumoural CpG injection leads to complete tumour eradication in mice bearing HPV16expressing tumours.Vaccine,2007,25(32):6037-6046.
• [25]Dell K,Klein C,Gissmann L.Comparison of DNA-and mRNA-transfected mouse dendritic cells as potential vaccines against the human papillomavirus type16associated oncoprotein E7.Antivir Ther,2008,13(4):495-509
• [26]Kim JH,Kang TH,Noh KH,et al.Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+)T cell-mediated cell death.Immunol Lett,2009,122(1):58-67.
• [27]Kang TH,Lee JH,Noh KH,et al.Enhancing dendritic cell vac-cine potency by combining a BAK/BAX siRNA-mediated anti-apoptotic strategy to prolong dendritic cell life with an intracellu-lar strategy to target antigen to lysosomal compartments.Int J Cancer,2007,120(8):1696-1703.